{"id":337,"date":"2022-05-04T13:41:54","date_gmt":"2022-05-04T11:41:54","guid":{"rendered":"https:\/\/bcamonitor.org\/?p=337"},"modified":"2026-09-22T13:33:41","modified_gmt":"2026-09-22T13:33:41","slug":"30300","status":"publish","type":"post","link":"https:\/\/bcamonitor.org\/?p=337","title":{"rendered":"Hey, it is bladder cancer awareness month in May!"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px|||||&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row admin_label=&#8221;row&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; custom_padding=&#8221;||4px|||&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; min_height=&#8221;280px&#8221; custom_padding=&#8221;|||1px||&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<p><span>The <strong>World Bladder Cancer Patient Coalition<\/strong> hosts this special month to highlight the facts about bladder cancer, promote awareness of the disease and call for more investment in research, treatment and care.<br \/> <\/span><\/p>\n<p>The theme of this year\u2019s edition \u201c<strong><em>Don\u2019t Go Red. Go To A Doctor<\/em><\/strong><em>\u201d <\/em>is to highlight the fact that blood in the urine is the most common symptom of bladder cancer [1]. More info <a href=\"https:\/\/worldbladdercancer.org\/awareness-month\/\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/p>\n<p><span>It is important to recognize and act on any symptoms, such as blood in urine, as soon as possible, because the prognosis for bladder cancer is favourable when the disease is detected early (i.e. when the disease is not yet muscle invasive). Despite the good prognosis, many patients with non-muscle-invasive bladder cancer (NMIBC) have recurrent disease following initial treatment. Recurrent NMIBC is typically not life-threatening, but here too <strong>early detection is important for a good prognosis<\/strong>. That is why surveillance of NMIBC is so important.<\/span><\/p>\n<p><span><\/span><\/p>\n<h5 style=\"text-align: center\"><strong>&#8211; A few facts on NMIBC surveillance &#8211;<\/strong><\/h5>\n<ul>\n<li><span>NMIBC has a 31-78% probability of recurrence at 5 years [2]<\/span><\/li>\n<li><span>Surveillance in NMIBC is of utmost important to detect recurrences early [1]<\/span><\/li>\n<li><span>Standard follow-up includes regular cystoscopy, which is an invasive procedure that poses a significant burden for both patients and healthcare systems<\/span><\/li>\n<li><span>Bladder cancer is one of the most expensive cancer to treat, partly due to the high surveillance costs [3]<\/span><\/li>\n<li><span>Cystoscopy is an invasive procedure and can cause discomfort and anxiety in patients<br \/> <\/span><\/li>\n<\/ul>\n<p><span>Don&#8217;t worry too much, there is good news too!<\/span><\/p>\n<p><span><\/span><\/p>\n<h5 style=\"text-align: center\"><strong>&#8211; Urinary biomarkers for NMIBC surveillance &#8211;<\/strong><\/h5>\n<p><span>The sensitivity of cystoscopy may be approached by 4 commercially available, non-invasive, urinary markers (Cxbladder Monitor, ADXBLADDER, Xpert Bladder Cancer Monitor and Bladder EpiCheck), as these tests have such high sensitivities and NPVs for high-grade disease [1]. For example, the Bladder EpiCheck\u00ae has a sensitivity of 91% and a NPV of 99% to detect high-grade bladder cancer [4]. Although RCTs are needed to draw firm conclusions, these promising results give us hope for a future in which the burden on patients and healthcare systems can be significantly reduced. <\/span><\/p>\n<p><span>Regarding these 4 urinary biomarkers, the EAU guidelines recently included in their guidelines for the surveillance of low-\/intermediate-risk NMIBC [1]:<\/span><\/p>\n<p style=\"text-align: center\"><em><span>These 4 tests might be used to replace and\/or postpone cystoscopy as they may identify<br \/> the rare high-grade recurrences occurring in low\/intermediate NMIBC [1].<\/span><\/em><\/p>\n<p><span>This is a huge milestone for the surveillance of NMIBC and opens the door for the use of non-invasive urinary biomarkers in clinical practice!<\/span><\/p>\n<p><span><\/span><\/p>\n<h5 style=\"text-align: center\"><strong>&#8211; What can you do? &#8211;<\/strong><\/h5>\n<p><span>You can actively support the Bladder Cancer Awareness Month campaign:<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14px\">Use these hashtags: #DontGoRed #BladderCancerMonth22<\/span><\/li>\n<li>Go to the <a href=\"https:\/\/worldbladdercancer.org\/awareness-month\/\" target=\"_blank\" rel=\"noopener noreferrer\" style=\"font-size: 14px\">awareness month page<\/a><span style=\"font-size: 14px\"> of the World Bladder Cancer Patient Coalition for more information<\/span><\/li>\n<\/ul>\n<p><span>You can help raise awareness on all aspects of bladder cancer, including:<\/span><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li><span>The fact that blood in urine as the most common symptom<\/span><\/li>\n<li><span>The importance of early detection of bladder cancer during diagnosis and surveillance<\/span><\/li>\n<li><span>The high burden of cystoscopy during surveillance of NMIBC<\/span><\/li>\n<li><span>The promising road ahead with the use of non-invasive urinary markers for bladder cancer surveillance<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<p><strong>References<\/strong><\/p>\n<ol>\n<li>Babjuk M, Burger M, Comp\u00e9rat E, et al. <span>European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Update March 2022.<\/span><\/li>\n<li>Sylvester RJ, van der Meijden APM, Oosterlinck W et al. Eur Urol 2006;49:466-5.<\/li>\n<li>Aly A, Johnson C, Doleh Y, et al. <span>J Clin Pathw 2020;6:51-60.<\/span><\/li>\n<li><span>Laukhtina E, Shim SR, Mori K et al. <\/span>Eur Urol Oncol 2021;4:927-42. Corrigendum in Eur Urol Oncol 2022;doi: 10.1016\/j.euo.2022.01.003.<\/li>\n<\/ol>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.8.2&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;2px||5px|||&#8221; global_module=&#8221;303&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The World Bladder Cancer Patient Coalition hosts this special month to highlight the facts about bladder cancer, promote awareness of the disease and call for more investment in research, treatment and care. The theme of this year\u2019s edition \u201cDon\u2019t Go Red. Go To A Doctor\u201d is to highlight the fact that blood in the urine [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":206,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-337","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication"],"_links":{"self":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=337"}],"version-history":[{"count":1,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/337\/revisions"}],"predecessor-version":[{"id":374,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/337\/revisions\/374"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/media\/206"}],"wp:attachment":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}